Real-Time PCR, Digital PCR and End-Point PCR Global Market Report 2024

The real-time pcr, digital pcr and end-point pcr market size has grown strongly in recent years. It will grow from $35.11 billion in 2023 to $38.37 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The increase observed in the historical period can be attributed to the standardization of PCR protocols, the role of PCR techniques in personalized medicine, their contribution to drug discovery and development, and the adoption of these techniques in forensic and paternity testing.

The real-time pcr, digital pcr and end-point pcr market size is expected to see strong growth in the next few years. It will grow to $54.95 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period can be attributed to the expansion of molecular diagnostics, the growth in infectious disease testing, increasing demand for genetic testing, market penetration in research and forensics, and the adoption of rapid point-of-care PCR solutions. Major trends expected in the forecast period involve the emergence of digital assays, advancements in multiplex PCR, a shift towards digital PCR technology, the automation of high-throughput systems, and the miniaturization of PCR platforms.

The anticipated rise in infectious diseases is set to drive the growth of the real-time PCR, digital PCR, and end-point PCR markets. Infectious diseases, caused by the proliferation of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, can be effectively addressed using PCR technologies. Real-time PCR, digital PCR, and end-point PCR play crucial roles in quantifying specific pathogens or their genetic material, monitoring disease progression, and swiftly diagnosing infections such as HIV, hepatitis, respiratory viruses, and tuberculosis. For instance, UNAIDS reported a global increase in the population living with HIV to 39 million in 2022, representing a 3.17% rise from 37.7 million in 2020, with approximately 1.3 million new HIV infections reported in 2022. Moreover, in the United States, the Centers for Disease Control and Prevention noted a rise in tuberculosis cases to 8,300 in 2022 from 7,874 in 2021. Thus, the escalating incidence of infectious diseases is a driving force behind the growth of the PCR markets.

The growth of chronic diseases is poised to propel the real-time PCR, digital PCR, and end-point PCR markets. Chronic diseases, persistent over an extended period and often worsening over time, are a significant focus for PCR applications. Real-time PCR aids in the early and accurate diagnosis of chronic conditions by detecting specific DNA or RNA markers associated with diseases such as cancer, diabetes, and viral infections. The World Health Organization reported 41 million deaths globally annually, with 74% attributed to non-communicable diseases, including 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the increasing prevalence of chronic diseases is a key driver for the real-time PCR, digital PCR, and end-point PCR markets.

A potential challenge lies in the declining demand for PCR testing for COVID-19, which may restrict market growth. The real-time RT-PCR test, commonly used for COVID-19 detection, faces challenges such as false-negative and false-positive results due to various factors. The declining nationwide rate of PCR testing, as reported in Australia with a daily average dropping from approximately 280,220 tests to 250,000 tests, may impact the market negatively. Consequently, the decreasing demand for PCR testing for COVID-19 poses a hindrance to the growth of the real-time PCR, digital PCR, and end-point PCR markets.

Key players in the real-time PCR, digital PCR, and end-point PCR markets are actively pursuing the development of innovative products, leveraging advanced technologies such as digital polymerase chain reaction (dPCR). This cutting-edge biotechnological refinement of conventional PCR methods enables the direct quantification and clonal amplification of nucleic acid strands, encompassing DNA, cDNA, or RNA. Notably, major companies are at the forefront of adopting dPCR technology to gain a deeper understanding of patients' conditions, whether related to cancer, genetic diseases, or infections. An illustrative example is Roche Diagnostics, a prominent US-based manufacturer of medicines and medical devices, which unveiled the next-generation Digital LightCycler System in August 2022. Specifically designed for the early detection and treatment of various chronic and genetic disorders, this advanced system introduces automation to workflow and data management. It eliminates the need for external calculations, software, and processors. Boasting three nano well plate configurations, six advanced optical channels, and 5x concentrated DNA and RNA master mixes, the Digital LightCycler System ensures high sensitivity and precision. This addition enhances Roche's diagnostic platforms, offering advanced technology, clinical applications, customization and flexibility, along with streamlined workflow automation.

In June 2021, Hologic Inc., a US-based medical technology company, completed the acquisition of Mobidiag Oy Ltd. for a substantial $795 million. This acquisition is positioned to fortify and expand Hologic's diagnostic businesses globally, leveraging Mobidiag's expertise in providing multiplex capability, particularly in fast-growing acute care adjacencies. The collaboration between the two companies aims to offer a high-throughput point-of-care growth platform, facilitating rapid treatment decisions during patient diagnosis. Mobidiag Oy Ltd., headquartered in Finland, specializes in the development and marketing of PCR-based tests for infectious diseases, including high-impact areas such as COVID-19, influenza, and antibiotic-resistant bacteria.

Major companies operating in the real-time pcr, digital pcr and end-point pcr market report are F. Hoffmann La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Co., GE HealthCare Technologies Inc., Agilent Technologies Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., Eppendorf Group, Promega Corporation, Meridian Bioscience Inc., Takara Bio Inc. , Cole-Parmer Instrument Company LLC, Bioneer Corporation, Enzo Life Sciences Inc., Analytik Jena AG , Fluidigm Corporation, Elitech Group SAS, Microsynth AG, Stilla Technologies SAS, HTG Molecular Diagnostics Inc., AITbiotech Pte Ltd., Bio Molecular Systems, JN Medsys Pte Ltd., Biomeme Inc.

North America was the largest region in the real-time PCR, digital PCR, and end-point PCR market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the real-time pcr, digital pcr and end-point pcr market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the real-time pcr, digital pcr and end-point pcr market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The real-time PCR, digital PCR, and end-point PCR market include revenues earned by entities by providing services such as quantitative analysis, real-time monitoring, high sensitivity and specificity, gene expression analysis, absolute quantification, rare event detection, qualitative detection, and molecular cloning. The market value includes the value of related goods sold by the service provider or included within the service offering. The real-time PCR, digital PCR, and end-point PCR market also include sales of thermal cyclers, fluorescent probes, quantitative data output, standard curves, real-time PCR reagents, partitioning chips or plates, digital PCR instruments, and PCR master mixes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main products associated with real-time PCR, digital PCR, and endpoint PCR include instruments, consumables and reagents, software, and services. Instruments refer to devices, tools, or equipment designed for measurement, analysis, manipulation, or control of physical, chemical, or biological phenomena. Various technologies, such as quantitative, endpoint PCR, and digital PCR, are used for clinical, research, forensic, and other applications, with different end-users including hospitals, diagnostic labs, pharmaceutical and biotechnology companies, and contract research organizations.

The real-time PCR, digital PCR and end-point PCR market research report is one of a series of new reports that provides real-time PCR, digital PCR and end-point PCR market statistics, including real-time PCR, digital PCR and end-point PCR industry global market size, regional shares, competitors with a real-time PCR, digital PCR and end-point PCR market share, detailed real-time PCR, digital PCR and end-point PCR market segments, market trends and opportunities, and any further data you may need to thrive in the real-time PCR, digital PCR and end-point PCR industry. This real-time PCR, digital PCR and end-point PCR market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.